Clinical outcomes of third-line chemotherapy prior to best supportive care in patients with stage IV colorectal cancer: a single-center study from Japan
This study demonstrates that third-line chemotherapy incorporating oral anticancer drug and bevacizumab (B-mab) following standardized treatment is a safe and effective option for Japanese patients with stage IV CRC. The regimen was associated with a manageable safety profile and encouraging long-term outcomes and may contribute to improved quality of life and quality-adjusted life years prior to transition to best supportive care.
Authors
- Masaya Mukai (ORCID: https://orcid.org/0000-0002-4931-0910)
- Kazutake Okada (ORCID: https://orcid.org/0009-0001-6268-7165)
- Lin Fung Chan
- Kyoko Kishima
- Hideki Izumi (ORCID: https://orcid.org/0000-0003-0080-7106)
- Shigeya Takeo
- Shigeo Higami (ORCID: https://orcid.org/0000-0002-5720-6662)
- Tomoki Nakamura
- Kazuhito Nabeshima
- Junichi Kaneko (ORCID: https://orcid.org/0000-0002-1284-5639)
- Souichirou Yamamoto
- Hiroyasu Makuuchi
Institutions
- Tokai University Hachioji Hospital (JP)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-10-01
- DOI
- https://doi.org/10.21037/jgo-2025-479
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00